RESUMEN
Starting in 2020, the global health system faced unprecedent challenges due to the coronavirus disease 2019 (COVID-19) pandemic and the consequences are still felt. All the more fascinating and of particular importance for health policy was the development of potent vaccines within about one year by several research groups after the first reports of COVID-19 infections. To date, three types of COVID-19 vaccines are available, i.e., messenger RNA-based vaccines, adenoviral vector vaccines, and inactivated whole-virus vaccines. We report a woman who developed reddish, partially urticarial skin lesions on her right arm and flank shortly after the first dose with the corona vaccination from AstraZeneca/Oxford (ChAdOx1). The lesions were transient, however reoccurred in loco and at other locations over several days. The clinical presentation was unusual and was correctly assigned due to the clinical course.
Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Enfermedades de la Piel , Urticaria , Femenino , Humanos , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , Emociones , Vacunas de ARNm , PalidezAsunto(s)
Neoplasias Primarias Secundarias/diagnóstico , Neurofibroma/diagnóstico , Neoplasias del Sistema Nervioso Periférico/diagnóstico , Neuropatía Tibial/diagnóstico , Diagnóstico Diferencial , Femenino , Humanos , Metástasis Linfática/diagnóstico , Melanoma/secundario , Persona de Mediana Edad , Neoplasias Cutáneas/patologíaRESUMEN
BACKGROUND: Schnitzler syndrome is a rare disease characterized by a chronic urticarial eruption and monoclonal gammopathy, as well as clinical and laboratory signs of inflammation. The pathophysiology is still unknown, although various autoantibody-mediated mechanisms have been described. Complete remission of symptoms has been reported recently in patients with Schnitzler syndrome treated with anakinra, an interleukin-1 receptor antagonist. METHODS: Two patients with Schnitzler syndrome treated with anakinra therapy are presented. RESULTS: We report two cases of nearly complete remission of symptoms in Schnitzler syndrome after the initiation of anakinra therapy, and the first observation of a relapse under continuous daily anakinra therapy. A review of the published literature on the treatment of Schnitzler syndrome with anakinra is presented. CONCLUSIONS: Based on published data, monotherapy with anakinra is currently the most promising treatment for Schnitzler syndrome, because it is able to induce complete remission of symptoms.